title: Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy.
abstract: OBJECTIVE
  Cognitive-behavioral therapy (CBT) is well documented as an efficacious treatment for panic disorder. We provided open CBT treatment to patients who subsequently participated in a maintenance treatment study. This article reports on predictors and trajectory of response in 381 participants who completed treatment at 4 sites.
  
  
  METHODS
  Participants who met criteria for panic disorder with or without agoraphobia (N = 381) completed assessment and entered treatment. Of these, 256 completed 11 sessions of CBT delivered by trained and supervised research therapists. Raters trained to reliability obtained demographic data and administered structured diagnostic interviews and the Hamilton Rating Scales for Depression and Anxiety and the Panic Disorder Severity Scale (PDSS) measures at baseline and posttreatment. We obtained self-report (SR) measures of anxiety sensitivity and adult separation anxiety at baseline and posttreatment and PDSS-SR ratings weekly. The study was conducted between November 1999 and July 2002.
  
  
  RESULTS
  Treatment response rate was 65.6% for completers and 44.1% for the intent-to-treat sample. Greater severity of panic disorder and lower levels of adult separation anxiety predicted response. Beginning at week 4, responders showed greater mean decreases in PDSS scores than non-responders and maintained the advantage throughout the treatment. By week 6, 76% of responders, compared to 36% of nonresponders, recorded PDSS scores at least 40% below baseline on 2 consecutive weeks (odds ratio = 5.42, 95% CI = 3.10 to 9.48).
  
  
  CONCLUSIONS
  These results suggest that CBT is just as effective for more severe panic disorder patients as it is for those with less severe panic disorder, regardless of other comorbid disorders, including agoraphobia. However, patients experiencing adult separation anxiety disorder are less likely to respond. Our results further inform clinicians that many people who will respond to 11 weeks of treatment will have done so by the middle of the treatment.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA. cindy.aaronson@mssm.edu
authors.forename: Cindy J
authors.initials: CJ
authors.lastname: Aaronson
authors.forename: M Katherine
authors.initials: MK
authors.lastname: Shear
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Goetz
authors.forename: Laura B
authors.initials: LB
authors.lastname: Allen
authors.forename: David H
authors.initials: DH
authors.lastname: Barlow
authors.forename: Kamila S
authors.initials: KS
authors.lastname: White
authors.forename: Susan
authors.initials: S
authors.lastname: Ray
authors.forename: Roy
authors.initials: R
authors.lastname: Money
authors.forename: John R
authors.initials: JR
authors.lastname: Saksa
authors.forename: Scott W
authors.initials: SW
authors.lastname: Woods
authors.forename: Jack M
authors.initials: JM
authors.lastname: Gorman
mesh_terms: D000328:Adult; D001010:Anxiety, Separation / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D001569:Benzodiazepines / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D039721:Diagnostic and Statistical Manual of Mental Disorders; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires
chemical_list: D001569:Benzodiazepines